Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II observer-blinded study of MenACWY-TT versus Menactra in healthy subjects aged 10 to 25 years
2012-001305-25Phase 2
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, single-blind trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine in meningococcal disease (3 arms), sponsored by GSK. Primary endpoint: Immunogenicity with respect to vaccine components.
02
Drugs
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-001305-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001305-25.